|Plate Blocking:||2% BSA Blocking Buffer|
|Formulations||Clear, 96-well plates, coated with 100μL of Streptavidin tetramer, blocked with 300μL of 2% BSA Blocking Buffer and captured 0.1 μg/well of biotinylated SARS-CoV2 Spike S1 protein.|
Flexible experimental design because of the plate consist with detachable 8-well strips.
Save your experiment time by pre-coated and blocked.
No denaturing of the protein component of a conjugate upon binding.
Ideal for binding anti-SARS2-CoV-2 antibodies or ACE2 protein that typically exhibit poor binding to polystyrene.
The unopened plate should be stored at 2°C to 8°C,The expiry date of the plate is 12 months. Once opened, place unused plates in a resealable bag with desiccant and store at 2°C to 8°C, The shelf life is 1 month from the date of opening.
Example ELISA Procedure.
Your experiment will include 5 simple steps:
a) Blocking the plate and wash the plate.
b) Add your sample to the plate, take the Anti-SARS-CoV-2 antibody or ACE-2 protein as Control sample. Incubation and wash the plate.
c) Add a diluted Secondary antibody HRP-Goat anti-Human IgG, Fc to the plate and incubation.
d) Wash the plate and next add TMB or other colorimetric HRP substrate.
e) Stop the substrate reaction by add diluted acid, and Read OD at 450 nm, the OD Value reflects the amount of antibody bound.
Example Biopanning Procedure
Immobilized biotinylated SARS-CoV2 Spike S1 protein at 1 μg/mL (100 μL/well) on Streptavidin Coated Plates, Clear, 96-Well (Cat. No. SP-11), can bind anti-SARS-CoV-2 S1 antibody with a linear range of 0.1-3 ng/mL (QC tested).
Immobilized biotinylated SARS-CoV2 Spike S1 protein at 1 μg/mL (100 μL/well) on Streptavidin Coated Plates, Clear, 96-Well (Cat. No. SP-11), can bind ACE2 with a linear range of 0.2-4 ng/mL (QC tested).
Price(USD) : $260.00
Price(USD) : $970.00
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
This web search service is supported by Google Inc.